Abstract
There are many difficulties associated with the late stages of Parkinson's disease (PD), but psychosis and agitation may be the most disturbing for both patients and care givers, and often precipitate the pivotal decision for long-term nursing home placement. While the addition of antipsychotic drugs or the withdrawal of antiparkinsonian drugs may improve the behavioral problem, these strategies usually worsen the motor difficulties. Clozapine has been studied in PD for over a decade, and while it appears to be effective, there are safety and tolerability concerns associated with it. In addition, in New Jersey, Medicaid no longer pays for the home blood draws that are required for home-bound patients. This led to a situation in which we had patients who needed to stop clozapine and begin an alternative therapy. Because quetiapine seems particularly well suited to patients with PD based on in vitro and in vivo studies we have begun to try this medication in PD patients who need to stop clozapine. This article reports three case histories of patients with PD, confusion and dopamimetic psychosis who had been previously managed with clozapine and who were successfully switched to quetiapine. At doses from 12.5 to 150 mg/day quetiapine was well tolerated, resulting in behavioral improvement and no real increase in parkinsonism. These case histories raise the possibility that quetiapine may represent a viable alternative to clozapine in PD patients with dopamimetic psychosis and behavioral disturbances.
Similar content being viewed by others
REFERENCES
Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993; 43:2227–2229
Ruggieri S, De Pandis MF, Bonamartini A, Vacca L, Stocchi F: Low dose clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin Neuropharmacol 1997; 20(3):204–209
Auzou P, Ozsancak C, Hannequin D, Moore N, Augustin P. Clozapine for the treatment of psychosis in Parkinson's disease: a review. Acta Neurol Scand 1996; 94:329–336
Hughes AJ. Drug treatment of Parkinson's disease in the 1990s: achievements and future possibilities. Drugs 1997; 53(2):195–205
Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patient with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56:556–559
Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994: 344:681
McKeith IG, Ballard BG, Harrison RWS. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995; 346:699
Meco G, Alessandria A, Bonifati V, Giustine P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994; 343:1370–1371
Meco G, Alessandri A, Giurtine P, Bonifati V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: An open-label, long-term study. Movement Dis 1997; 12:4:610–611
Workman RH, Orengo CA, Bakey AA, Molinari VA, Kunik ME. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsychiatry Clin Neurosci 1997; 9:594–597
Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients. Neurology 1996 Oct; 47(4):1085–1087
Jimenez-Jimenez FJ, Tallon-Barranco A, Orti-Pareja M, Zurdo M, Porta J, Molina JA. Olanzapine can worsen parkinsonism. Neurology 1998 Apr; 50(4): 1183–1184
Friedman J. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1998 Apr; 50(4): 1195–1196
Gefvert O, Lindstrom LH, Langstrom J, et al.: Time course for dopamine and serotonin receptor occupancy in the brain of schizophrenic patients following dosing with 150 mg of Seroquel (ici 204,636) tid. [abstract] Proc 34th ACNP Meeting 1998
Arnt J, Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharm 1998; 18(2):63–101
Parsa M, Bastini B. Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease. J Neuropschiatry 1998; 10(2):216–219
Jancos JL, Evatt ML, Jewart D. Long-term effects of quetiapine fumarate in Parkinsonism complicated by psychosis. Neurology 1998; 50(suppl 4): A70–A71
Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991; 39:708–716
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Menza, M.M.A., Palermo, B. & Mark, M. Quetiapine as an Alternative to Clozapine in the Treatment of Dopamimetic Psychosis in Patients with Parkinson's Disease. Ann Clin Psychiatry 11, 141–144 (1999). https://doi.org/10.1023/A:1022360027358
Issue Date:
DOI: https://doi.org/10.1023/A:1022360027358